Novas perspectivas no manejo e tratamento da epilepsia
Escrito por: MDHealth em 25 de abril de 2023
5 min de leitura
Referências
Löscher W, Potschka H, Sisodiya SM, Vezzani A. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacol Rev. 2020 Jul;72(3):606-638. doi: 10.1124/pr.120.019539. PMID: 32540959; PMCID: PMC7300324.BRASIL.
Ministério da Saúde. Secretaria de Atenção à Saúde. Protocolo clínico e diretrizes terapêuticas: epilepsia. Brasília: Ministério da Saúde, 2018.
Ortiz de la Rosa JS, et al., Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review. Seizure. 2018 Mar;56:34-40. doi: 10.1016/j.seizure.2018.01.014. Epub 2018 Feb 8. PMID: 29428899.
Asadi-Pooya AA, et al., A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. Epilepsia. 2020 Aug;61(8):1668-1677. doi: 10.1111/epi.16610. Epub 2020 Jul 22. PMID: 32697354.
Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000 Jul 25;55(2):236-42. doi: 10.1212/wnl.55.2.236. PMID: 10908898.